Rein Therapeutics (RNTX) Company Overview

Profile

Full Name:

Rein Therapeutics Inc.

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

June 29, 2017

Indexes:

Not included

Website:

http://www.reintx.com

Description:

Rein Therapeutics is a biotechnology company focused on developing innovative treatments for various diseases, aiming to improve patient outcomes through advanced research and technology.

Key Details

Price

$2.44

Market Cap

$52.86 M(Small cap)

Last Dividend

-

TTM Dividend Yield

-

Annual Revenue

-

Annual EPS

-$3.42(+43.19% YoY)

PE Ratio

-

Annual ROE

-228.43%

Annual Debt To Equity

0.01

Beta

7.44

Events Calendar

Earnings

Next earnings date:

Apr 15, 2025

Recent quarterly earnings:

Nov 14, 2024

Recent annual earnings:

Apr 15, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

No data about analysts updates

Screeners with RNTX included

No data

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Current Price

$2.44
RNTX price is $2.44

Price All-time High

$2.44
RNTX price is currently at an all-time high

Price Analysts Target

$13.00
RNTX price is currently -81.23% lower than the consensus analysts' forecast

Price Most Recent Change

+3.83%
RNTX price was up +3.83% on Feb 19, 2025

Price YTD Change

-
RNTX price ytd change is unknown

Price 3-Year Change

-
RNTX price 3-year change is unknown

Market cap

Market Cap

$52.86 M
RNTX market capitalization is $52.86 million

Market Cap 3-Year Change

-
RNTX market capitalization 3-year change is unknown

Market Cap All-time High

$52.86 M
RNTX market capitalization is currently at an all-time high

Market Cap Sector Rank

35.53%
RNTX market capitalization is higher than 35.53% of companies in Healthcare sector

Technical

Beta

7.44
RNTX beta is 7.44

200-day SMA

$2.25
RNTX price is currently +8.36% above its 200-day simple moving average

14-day RSI

67.25
RNTX 14-day relative strength index is 67.25

30-day Relative Volume

2.95
RNTX 30-day relative volume is 2.95

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Annual Revenue

-
RNTX annual revenue value is unknown

Annual Revenue Analysts Estimate

-
RNTX annual revenue consensus analysts' forecast is unknown

Annual Revenue 1-Year Change

-
RNTX annual revenue 1-year change is unknown

Annual Revenue Sector Rank

-
RNTX annual revenue is unknown

Profit

Annual Gross Profit

-
RNTX annual gross profit value is unknown

Annual Gross Margin

-
RNTX annual gross profit margin value is unknown

Annual Operating Profit

-$15.35 M
RNTX annual operating income is -$15.35 million

Annual Operating Margin

-
RNTX annual operating profit margin value is unknown

Annual Net Income

-$15.73 M
RNTX annual net profit is -$15.73 million

Annual Net Margin

-
RNTX annual net profit margin value is unknown

EPS

Annual EPS

-$3.42
RNTX annual earnings per share is -$3.42

Annual EPS Analysts Estimate

-$2.24
RNTX annual earnings per share is currently +52.68% higher than the consensus analysts' forecast

Annual EPS 1-Year Change

+43.19%
RNTX annual earnings per share is up +43.19% year-on-year

Annual EPS Sector Rank

-
RNTX annual earnings per share is unknown

ROA & ROE

Annual ROA

-14.84%
RNTX annual return on assets is -14.84%

Annual ROE

-228.43%
RNTX annual return on equity is -228.43%

EBIT & EBITDA

Annual EBIT

-$15.35 M
RNTX annual earnings before interest & taxes is -$15.35 million

Annual EBITDA

-$15.23 M
RNTX annual EBITDA is -$15.23 million

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PE Ratio

-
RNTX price to earnings ratio value is unknown

PE Ratio Sector Rank

-
RNTX price to earnings ratio is unknown

PB Ratio

PB Ratio

1.05
RNTX price to book ratio is 1.05

PB Ratio Sector Rank

42.32%
RNTX price to book ratio is higher than 42.32% of companies in Healthcare sector

PS Ratio

PS Ratio

-
RNTX price to sales ratio value is unknown

PS Ratio Sector Rank

-
RNTX price to sales ratio is unknown

Enterprise value

Enterprise Value

$35.21 M
RNTX enterprise value is $35.21 million

Enterprise Value Sector Rank

34.74%
RNTX enterprise value is higher than 34.74% of companies in Healthcare sector

EV/EBITDA

EV/EBITDA

-1.19
RNTX EV/EBITDA is -1.19

EV/EBITDA Sector Rank

45.32%
RNTX EV/EBITDA is higher than 45.32% of companies in Healthcare sector

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Annual Current Ratio

4.17
RNTX annual current ratio is 4.17

Annual Quick Ratio

-
RNTX annual quick ratio value is unknown

Leverage

Annual Debt To Equity

0.01
RNTX annual debt to equity ratio is 0.01

Annual Interest Coverage Ratio

-
RNTX annual interest coverage ratio value is unknown

Risk & Stability

Piotroski F-Score

-
RNTX piotroski f-score value is unknown

Altman Z-Score

-
RNTX altman z-score value is unknown

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Annual Total Assets

$106.01 M
RNTX annual total assets is $106.01 million

Annual Non Current Assets

$87.74 M
RNTX annual long term assets is $87.74 million

Annual Current Assets

$18.27 M
RNTX annual total current assets is $18.27 million

Annual Cash & Cash Equivalents

$17.31 M
RNTX annual cash & cash equivalents is $17.31 million

Equity

Annual Book Value

$6.89 M
RNTX annual book value is $6.89 million

Annual Working Capital

$13.88 M
RNTX annual working capital is $13.88 million

Liabilities

Annual Total Liabilities

$99.12 M
RNTX annual total liabilities is $99.12 million

Annual Total Long Term Liabilities

$94.74 M
RNTX annual total long term liabilities is $94.74 million

Annual Current Liabilities

$4.38 M
RNTX annual total current liabilities is $4.38 million

Annual Accounts Payable

$1.19 M
RNTX annual accounts payable is $1.19 million

Debt

Annual Total Debt

$48.00 K
RNTX annual total debt is $48.00 thousand

Annual Total Debt 1-Year Change

+45.45%
RNTX annual total debt is up +45.45% year-on-year

Annual Long Term Debt

-
RNTX annual long term debt value is unknown

Annual Short Term Debt

$48.00 K
RNTX annual short term debt is $48.00 thousand

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Annual Total Expenses

$15.35 M
RNTX annual total expenses is $15.35 million

Annual Operating Expenses

$15.35 M
RNTX annual total operating expenses is $15.35 million

Annual Cost Of Goods Sold

-
RNTX annual cost of goods sold value is unknown

Annual SGA

$11.36 M
RNTX annual SGA is $11.36 million

Annual D&A

$119.00 K
RNTX annual depreciation & amortization is $119.00 thousand

Annual Interest Expense

-
RNTX annual interest expense value is unknown

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Annual CFO

-$19.81 M
RNTX annual cash flow from operations is -$19.81 million

Annual CFO 1-Year Change

+20.34%
RNTX annual cash flow from operations is up +20.34% year-on-year

Annual CFI

$16.20 M
RNTX annual cash flow from investing activities is $16.20 million

Annual CFI 1-Year Change

-38.79%
RNTX annual cash flow from investing activities is down -38.79% year-on-year

Annual CFF

$15.79 M
RNTX annual cash flow from financing activities is $15.79 million

Annual CFF 1-Year Change

+100%
RNTX annual cash flow from financing activities is up +100% year-on-year

Free CashFlow

Annual FCF

-$19.81 M
RNTX annual free cash flow is -$19.81 million

Annual FCF 1-Year Change

+20.34%
RNTX annual free cash flow is up +20.34% year-on-year

CAPEX

Annual CAPEX

-
RNTX annual capital expenditures value is unknown

Annual CAPEX 1-Year Change

-
RNTX annual capital expenditures 1-year change is unknown

Institutional Ownership

Similar stocks

ALRN logo
Aileron Therapeutics (ALRN)
OTLK logo
Outlook Therapeutics (OTLK)
Abpro (ABP)
ESLA logo
Estrella Immunopharma (ESLA)
ITRM logo
Iterum Therapeutics (ITRM)
IMMX logo
Immix Biopharma (IMMX)
SER logo
Serina Therapeutics (SER)
TNXP logo
Tonix Pharmaceuticals Holding (TNXP)
HBIO logo
Harvard Bioscience (HBIO)

FAQ

  • What is the ticker symbol for Rein Therapeutics?
  • Does Rein Therapeutics pay dividends?
  • What sector is Rein Therapeutics in?
  • What industry is Rein Therapeutics in?
  • What country is Rein Therapeutics based in?
  • When did Rein Therapeutics go public?
  • Is Rein Therapeutics in the S&P 500?
  • Is Rein Therapeutics in the NASDAQ 100?
  • Is Rein Therapeutics in the Dow Jones?
  • When was Rein Therapeutics's last earnings report?
  • When does Rein Therapeutics report earnings?

What is the ticker symbol for Rein Therapeutics?

The ticker symbol for Rein Therapeutics is NASDAQ:RNTX

Does Rein Therapeutics pay dividends?

No, Rein Therapeutics does not pay dividends

What sector is Rein Therapeutics in?

Rein Therapeutics is in the Healthcare sector

What industry is Rein Therapeutics in?

Rein Therapeutics is in the Biotechnology industry

What country is Rein Therapeutics based in?

Rein Therapeutics is headquartered in United States

When did Rein Therapeutics go public?

Rein Therapeutics's initial public offering (IPO) was on June 29, 2017

Is Rein Therapeutics in the S&P 500?

No, Rein Therapeutics is not included in the S&P 500 index

Is Rein Therapeutics in the NASDAQ 100?

No, Rein Therapeutics is not included in the NASDAQ 100 index

Is Rein Therapeutics in the Dow Jones?

No, Rein Therapeutics is not included in the Dow Jones index

When was Rein Therapeutics's last earnings report?

Rein Therapeutics's most recent earnings report was on Nov 14, 2024

When does Rein Therapeutics report earnings?

The next expected earnings date for Rein Therapeutics is Apr 15, 2025